All News
Filter News
Found 55 articles
-
Elicio Therapeutics Presents Updated Preclinical Data at Vaccines Summit Boston 2022 on ELI-005, a Lymph Node-Targeted Amphiphile Vaccine, Demonstrating It Induces Potent Cross-Reactive Cellular and Humoral Immunity to SARS-CoV-2
3/29/2022
Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced positive preclinical data demonstrating that ELI-005, a protein subunit vaccine containing the spike receptor-binding domain (RBD) protein of SARS-CoV-2, and Elicio’s lymph node-targeted CpG TLR-9 agonist, Amphiphile-CpG (AMP-CpG), induce potent cross-reactive antibody and T cell responses in mice and non-human primates.
-
Elicio Therapeutics Presents Preclinical Data on its Amphiphile-CpG Adjuvant at the STING & TLR-Targeting Therapies Summit 2022 Digital Event
3/23/2022
Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced the presentation of preclinical data demonstrating that its lymph node-targeted CpG TLR9 agonist, Amphiphile-CpG (AMP-CpG), induces potent immune and anti-tumor responses, at the STING & TLR-Targeting Therapies Summit 2022 Digital Event.
-
CEO to CEO: Tips for First-time Founders
1/11/2022
BioSpace picked the brains of 10 biotech CEOs and founders, to solicit their advice for first-time founders. -
Elicio Therapeutics Presents Preclinical Data on AMP TCR-T and CAR-T Combination Therapies at the 2021 Society for Immunotherapy of Cancer Annual Meeting
11/12/2021
Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced two ePoster presentations of preclinical data on its Amphiphile (AMP) platform in combination with TCR-T and CAR-T therapies, respectively, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting taking place in Washington D.C. and virtually November 10-14, 2021.
-
Flare Therapeutics Appoints Daphne Karydas as COO and CFO, and Michaela Bowden, PhD, as SVP of Biology and Translation
10/25/2021
Flare Therapeutics today announced the appointment of Daphne Karydas as Chief Operating Officer and Chief Financial Officer, and Michaela Bowden, PhD, as Senior Vice President of Biology and Translation.
-
Elicio Therapeutics Announces First Patient Dosed in the ELI-002 (AMPLIFY-201) study in KRAS-Driven Cancers
10/6/2021
Elicio Therapeutics, today announced that the first patient has been dosed with ELI-002, an investigational lymph node-targeted therapeutic vaccine, by Shubham Pant, M.D. at MD Anderson as part of a Phase 1/2 (AMPLIFY-201) study evaluating its safety and efficacy as a treatment for patients with KRAS-driven tumors who have minimal residual tumor cells following surgery to remove the tumor.
-
September 24 is World Cancer Research Day, a time for patients, caregivers and companies on the forefront of cancer R&D to look back and look ahead.
-
Elicio Therapeutics Presents Updated Preclinical Data at the 2021 Vaccines Summit Demonstrating that ELI-005, a Lymph Node Targeted Amphiphile Vaccine, Induces Potent Cellular and Humoral Immunity to SARS-CoV-2
9/22/2021
Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced positive preclinical data demonstrating that ELI-005, a protein subunit vaccine containing the lymph node-targeted Amphiphile-CpG adjuvant (AMP-CpG), induces potent cellular and humoral immunity to SARS-CoV-2 at the 2021 Vaccines Summit.
-
Elicio Therapeutics Announces Virtual Presentation of Data on its Amphiphile-CpG Adjuvant at the Vaccines Summit 2021
9/17/2021
Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced that it will present preclinical data on its AMP-CpG adjuvant (AMP-CpG) at the Vaccines Summit 2021, being held virtually from September 20-22, 2021.
-
Elicio Therapeutics Presents Preclinical Data on AMP TCR-T Combination Therapy in Solid Tumors at the CAR-TCR Annual Summit 2021
9/10/2021
Elicio Therapeutics today announced that it presented preclinical data on its Amphiphile (AMP) platform in combination with TCR-T therapy in solid tumors at the 6th Annual CAR-TCR summit, that was held virtually from August 30 – September 2, 2021.
-
Clinical Catch-Up: June 28-July 2
7/6/2021
It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look. -
Elicio Therapeutics Announces Initiation of Its Phase 1/2 Dose-Escalation Study of ELI-002 (AMPLIFY-201) in KRAS-Driven Cancers
6/29/2021
Elicio Therapeutics today announced the initiation of AMPLIFY-201, a Phase 1/2 dose-escalation study evaluating the safety and preliminary efficacy of ELI-002.
-
Clinical Catch-Up: February 22-26
3/1/2021
It was another busy week for clinical trial news. Here’s a look. -
Money on the Move: February 17-23
2/24/2021
Life sciences companies across the globe are raking in investment dollars to advance drug programs. -
Elicio Therapeutics Announces FDA Clearance of IND Application for ELI-002 -- A Therapeutic Vaccine Targeting Mutated KRAS Cancers
2/23/2021
Elicio Therapeutics, a private biotechnology company developing a pipeline of potent immunotherapies based on its proprietary lymph-node targeting Amphiphile technology, announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for ELI-002. ELI-002 is an Amphiphile
-
Elicio Therapeutics Announces FDA Clearance of IND application for ELI-002-- A Therapeutic Vaccine Targeting mutated KRAS Cancers
2/23/2021
Elicio Therapeutics, a private biotechnology company developing a pipeline of potent immunotherapies based on its proprietary lymph-node targeting Amphiphile technology, announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for ELI-002. ELI-002 is an Amphiphile
-
Elicio Therapeutics Secures a Total of $73 Million in Series B Financing
2/17/2021
Proceeds will advance the lead asset ELI-002, a mKRAS therapeutic cancer vaccine, into a Phase 1/2 clinical trial. Platform technology innovation will continue development of next generation immunotherapies including AMP-adjuvant enabled vaccines, cell therapy programs, and more.
-
Elicio Therapeutics to discuss success of Amphiphiles enabled T cell therapies at CAR-TCR Digital Summit Europe
2/15/2021
Elicio Therapeutics , a private biotechnology company developing a pipeline of potent immunotherapies based on its proprietary lymph node targeting technology, today announced Christopher Haqq , M.D., Ph.D., Elicio’s Executive Vice President, Head of Research and Development, and Chief Medical Officer, will co-lead a workshop
-
Science Advances: Elicio Therapeutics’ SARS-CoV-2 Vaccine Demonstrates T Cell Responses >25 Fold Higher Than Benchmark Vaccines
2/5/2021
A proprietary lymph node targeting adjuvant for COVID-19 has elicited high magnitude T cell responses alongside potent neutralizing antibody induction; the studies are published in the February 5 issue of Science Advances.